Clearside, G1 price upsized follow-ons

Ophthalmology company Clearside Biomedical Inc. (NASDAQ:CLSD) and cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) each priced bumped-up follow-ons on the back of positive data, raising a total of $185.3 million.

Clearside raised $85 million through the sale of 6.5 million shares at $13 in a follow-on underwritten by J.P. Morgan, Cowen, Stifel, Needham and Wedbush. The price is a small premium over Clearside's closing price of $12.95 on Tuesday, when the company proposed after market hours to raise $75 million. Clearside climbed 10% on Wednesday, and then priced the offering after market close. Its shares slipped $1.28 to $13 on Thursday...